Title Image

R&D

Quetiapine XR
Indication Schizophrenia
Status ­ ‒ ­ US Launched in November 2016 by Par Pharmaceutical.
­ ‒ ­ Canada Launched by a commercialization partner of Handa.
Product Advantages ­ ‒ ­ First- to File, 180-day market exclusivity right in the USA.
­ ‒ ­ Final approval for 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg.
Market Size Handa has received profit sharing of more than $20 million in the USA and more than $3.5 million in Canada.

judi online infini88 slot pg slot baccarat online slot idn live idn poker judi bola tangkasnet pragmatic slot88 sbobet slot deposit dana casino online vegas slot pokerseri joker123 autowin88 warungtoto selot